( ithout antigen presentation capabilitie...)Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer,Health

MAGE-A3 antigen has been in-licensed by GSK from the Ludwig Institute for Cancer Research, the largest international academic institute dedicated to understanding and controlling cancer. MAGE-A3 ASCI is an investigational compound and it is not approved for use in any indication in any country at this time.

About Non-Small Cell Lung Cancer

According to the World Health Organization (WHO), more than 1.3 million new cases of lung and bronchus cancer are diagnosed each year worldwide(1). The American Cancer Society estimates that approximately 213,380 new cases of lung and bronchus cancer and more than 162,000 related deaths will occur in the United States in 2007. It is the leading cause of cancer death in the United States for both men and women. Non-Small Cell Lung Cancer is the most common form of lung cancer, accounting for about 80 to 85 percent of all lung cancers(2). Approximately 35 percent to 50 percent of early NSCLC expresses MAGE-A3(1).

About GlaxoSmithKline and GlaxoSmithKline Biologicals

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. GSK Bio is also developing innovative immunotherapy compounds to treat cancer patients.

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information please visit www.gsk.com.

        Enquiri
'"/>




Page: 1 2 3 4 5 6 
Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase
2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Ambrilia Highlights Encouraging Data for its HIV Integrase
Inhibitor Program and Recent Developments at Annual Meeting
3. Pharmions Amrubicin Shows Encouraging Results Compared to Standard
of Care in Second Line Treatment of Small Cell Lung Cancer
4. Merck at ASCO 2007: Encouraging Results in Progression-Free
Survival in Patients With Aggressive Brain Tumors (glioblastoma)
Using Cilengitide in Phase I/IIa Study
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S.,
From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe
Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease